Corprate Bias Ratings
Boehringer Ingelheim, a German pharmaceutical company, fired a small number of employees after they allegedly refused to comply with the company's vaccine mandate. Boehringer vets vendors according to LGBTQ policies and does not provide its employees with protections against viewpoint discrimination. It has not publicly terminated business relationships based on views or beliefs. Boehringer advocates for the Equality Act and opposes Florida's Parental Rights in Education Law. The company covers the cost of "medically necessary transition-related care” for its employees and their children. However, it does not seem to discriminate against religious organizations in its charitable giving and does not use its corporate dollars or PAC contributions for ideological purposes. For these reasons, Boehringer Ingelheim receives a Medium Risk rating.
Charitable giving (including employee matching programs) policies or practices discriminate against charitable organizations based on views or religious beliefs.
Uses corporate reputation to support ideological causes and/or organizations hostile to freedom of expression.
Boehringer Ingelheim has also signed open letters supporting the Equality Act (1). The company was part of the Freedom for All Americans coalition, which advocated for federal legislation that would overrule state laws designed to protect girls’ sports and similar laws (2). The company also signed an open letter opposing the Florida Parental Rights in Education Act, which prohibits teaching gender identity and sexual orientation in schools to children in K-3rd grade (3). Boehringer developed “U.S. Workplace Gender Transition Guidelines,” including hormone replacement therapy, psychological therapy, and gender-affirming surgical procedures that it developed directly in coordination with the HRC (4)(5). The company has updated protocols to include transgender individuals in their clinical trials as well (6).
Uses corporate funds to advance ideological causes, organizations, or policies hostile to freedom of expression.
All links were last accessed and all information was updated on:
November 28, 2023
Company reports are intended for educational use only. Full Disclaimer